89bio, a San Francisco-based clinical-stage biopharmaceutical company, has successfully raised $125 million in its latest funding round, further propelling its mission to develop innovative therapies for liver and cardio-metabolic diseases. Focused on addressing critical medical needs, 89bio is dedicated to improving the lives of patients suffering from nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG) with its lead product candidate, BIO89-100. This specifically engineered glycoPEGylated analog of FGF21 has shown promising Phase 1b/2a results, demonstrating not only a favorable safety and tolerability profile but also significant reductions in liver fat and key lipid markers when administered weekly or bi-weekly. The recent funding will be instrumental in advancing BIO89-100 through its ongoing Phase 2 trial for SHTG and expediting further clinical development efforts aimed at transforming treatment options for patients with liver diseases. 89bio prides itself on a culture rooted in patient-centric values and operates with unwavering integrity and ethical standards. The talented team fosters an environment that encourages collaboration and entrepreneurship, driving scientific rigor in their decision-making. With this substantial financial backing, 89bio is poised to make a significant impact in the biopharmaceutical landscape and enhance the quality of life for individuals battling complex liver and metabolic disorders. The momentum gained from this funding will undoubtedly accelerate the timeline for bringing innovative therapies from the lab to the clinic, underscoring the company's commitment to leading advancements in patient care.
New Milestone Reached: 89bio Secures $125 Million Funding for Breakthrough Liver and Cardio-metabolic Therapies
Recently funded 路 $125.0MBiopharmaceutical
Get the full 89bio company profile
Access contacts, investors, buying signals & more
Other recently funded companies
View all
Laihua Online
Wuhan Laihua Information and Technology is an Internet leading source of information on educational opportunities for students to study in other countries especially in China. Either prospect is planning to come to China or is already in China for education (self-support or scholarship based) he will probably need one of the ranges of services we provide from Education, Translation, Notarization of legal documents to Internships & Jobs or Medical Tourism etc. It is a comprehensive directory of study abroad programs, including summer study abroad, service learning, intensive language programs and more. Wuhan Laihua Information and Technology first set out to fill the information gap between students with a desire to travel abroad to study and companies offering international programs.
$68.0M Series d
today
NEW ID
NEW ID is the latest subsidiary company of NEW, which has started up since August 2019 for a new digital contents/platform business domain. We are responsible for expanding the contents produced and acquired by NEW into various markets and creating our digital capabilities through partnering with a-lister digital content creators and providers in Korea.
